CLOs on the Move


 
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.erasca.com
  • 10835 Road to the Cure Suite 140
    San Diego, CA USA 92121
  • Phone: 858.465.6511

Executives

Name Title Contact Details
Chandra Lovejoy
Senior Vice President of Regulatory Affairs Profile
Ebun Garner
General Counsel and Corporate Secretary Profile
Cheryl Toland
Executive Director, Legal Profile
Cheryl Toland
Deputy General Counsel Profile

Similar Companies

Lipomics Technologies

Lipomics Technologies is a West Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affiliated Dermatologists, S.C.

Affiliated Dermatologists, S.C. is a Brookfield, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eastern Maine Medical Center Federal Credit Union aka EMMC FCU

Eastern Maine Medical Center Federal Credit Union aka EMMC FCU is a Bangor, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedWorxs

MedWorxs is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scifluor Life Sciences

SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics. The company is creating a portfolio of new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, more convenient dosing and better patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a range of therapeutic categories and disease areas including retinal disease, CNS disorders, fungal and bacterial infections and inflammatory disease.